Mesothelin (MSLN) shows increased expression in various cancer cells. For clinical application of antibodies as a positron emission tomography (PET) imaging reagent, a human shortened antibody is essential both for avoiding redundant immune responses and for providing rapid imaging. Therefore, we cloned a single-chain fragment of variable regions (scFv) from a human-derived gene sequence. This was achieved through the construction of a naïve phage library derived from human tonsil lymphocytes. Using a column with human recombinant MSLN, we carried out biopanning of phage-variants by colony formation. We first obtained 120 clones that were subjected to selection in an ELISA using human recombinant MSLN as a solid phase antigen, and 15 phage clones of scFv with a different sequence were selected and investigated by flow cytometry (FCM). Then, six variants were selected and the individual scFv gene was synthesized in the V L and V H domains and expressed in Chinese hamster ovary cells. Mammalian cell-derived human-origin scFv clones were analyzed by FCM again, and one MSLN highly specific scFv clone was established.
| INTRODUC TI ON
Mesothelin (MSLN) is a cell differentiation-related and cell surface glycoprotein (40 kDa) that includes a glycosylphosphatidylinositol (GPI) anchor. 1 In normal tissues, MSLN is expressed only in mesothelial cells in the pleura, peritoneum, and pericardium. However, in malignant tumors, MSLN is overexpressed in diverse types of cancers, such as ovarian cancer, gastric cancer, non-small cell lung cancer, breast cancer, pancreatic cancer, and malignant mesothelioma. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] MSLN and its variant, soluble MSLN-related peptide (SMRP), are possible biomarkers for malignant tumors. Commercially available ELISA to diagnose malignant mesothelioma based on recognition of SMRP are available. [14] [15] [16] [17] [18] [19] [20] [21] [22] A clinical trial of anti-MSLN mAb, amatuximab (MORAb-009), for the treatment of mesothelioma and pancreatic cancer is now underway.
Monoclonal antibodies have been applied as powerful clinical tools for diagnosis (for cancer imaging) and treatment. [23] [24] [25] However, full-length IgG has a long circulation time in the blood and undesirable characteristics, such as accumulation in the liver.
In contrast, small-sized antibody variants, such as single-chain fragment of variable region (scFv), diabody, minibody, and F(ab′) 2 can penetrate tumors and other tissues faster and more uniformly than full-length IgG. [26] [27] [28] [29] [30] A deletion of Fc domain allows evasion of immune detection. As a result, in vivo clearance of specific antibody is accelerated, and nonspecific accumulation is expected to be reduced. Furthermore, with these effects, highly specific imaging can be achieved in a shortened imaging period. Specificity to antigen in the molecule, ease of preparation by gene recombination, and high permeability to tumors because of its small molecular size make scFv an extremely attractive reagent. Nevertheless, PET imaging with scFv is presently rare other than in some cases of ovarian cancer. 31 In our previous PET imaging study, MSLN-positive tumors in xenografts were visibly detected by 64 Cu-radiolabeled fulllength mouse antihuman MSLN IgG, but it took 24-48 hours to get fine contrast as a result of the long half-life of IgG. 32 In the present study, we established a scFv from a human-origin gene sequence and rapid PET imaging (3 hours after the injection) of tumor regions was successfully demonstrated in xenografts using the scFv.
| MATERIAL S AND ME THODS

| Reagents
Deferoxamine-p-SCN (DFO) was purchased from Macrocyclics.
Amicon Ultra 0.5 centrifugal filter units were purchased from Merck
Millipore. Other chemicals were reagent grade.
| Construction of phage antibody library
Phage antibody library was constructed by using human tonsils removed from 15 patients with tonsil hypertrophy and inflammation as shown on schematic diagrams in Figure 1 . Single-chain Fv form of an antibody was fused to truncated cp3 (scFv-cp3) 33 and expressed on the phage surface. Two types of antibody libraries were constructed and used in this study. One was scFv-cp3 consisting of V H and V L sequences recovered from lymphocytes in the tonsils which was designated as H1. The other was scFv-C L -cp3
consisting of V H and V L -C L sequences from the same sample and designated as H2 ( Figure 1C ). This study was approved by the Okayama University Ethics Committee and Medical & Biological Laboratories Co., Ltd Ethics Committee and was implemented according to the Ethical Guidelines for Human Genome/Gene
Research enacted by the Japanese Government and the Helsinki Declaration.
| Screening of antihuman MSLN-scFv-cp3
Phages displaying scFv-cp3 which showed MSLN-binding activity were selected by a panning method. 
| Preparation of antihuman MSLN-scFv-His-Tag in mammalian cells
From the DNA sequence of a highly reactive scFv-cp3, we synthesized a scFv gene with a His-Tag sequence and expressed scFv using mammalian cells. Overall workflow for the preparation of humanized antihuman MSLN-scFv is shown in Figure 1C .
We synthesized an artificial gene of the V H and V L sequences of an anti-MSLN scFv-cp3 selected by ELISA and flow cytometry (FCM), and a linker and His-Tag were added to it. This gene was inserted into the mammalian cell expression vector pCx17. 4 (Lonza) and genetically transfected into CHOK1-GSKO. Molecular sizes of the purified scFv preparations were estimated by SDS-PAGE. We also measured the molecular weight of the scFv with MALDI-time of flight mass spectrometry (MALDI-TOF-MS) (AXIMA Performance; Shimadzu).
| Cell culture
Cancer cell lines established from various tissue types were purchased from ATCC and Japanese Collection of Research Bioresources (JCRB). Names of cell lines, tissue origins, and disease cases are shown in Table S1 . All cells were cultured at 37°C in an incubator humidified with 5% CO 2 .
| Flow cytometry analysis of antibodies
Human cancer cells (Table S1) sequences. PT7 has a T7 promoter. The variable region is shown in black, and the constant region is shown in gray. C, Schematic diagram of the preparation of an scFv with a His-Tag sequence and the concentration and selection of an scFv with a cp3 sequence (cp3-scFv). The cp3-scFv was concentrated by four to five rounds of bio-panning in a His-Tag column or mouse anti-His-Tag monoclonal antibody and Protein G column that uses beads to which human recombinant MSLN was bound. Individual cp3-scFv were cloned, and the binding ability to MSLN was evaluated by ELISA. scFv that were highly reactive according to ELISA were selected for their ability to bind to cancer cells, which was confirmed by flow cytometry (FCM). Based on the sequence information for selected scFv, we synthesized DNA of the scFv with a His-Tag sequence, expressed with Chinese hamster ovary (CHO) cells, and confirmed the ability to bind to cancer cells using FCM. scFv with a HisTag sequence that was highly reactive based on FCM were evaluated by positron emission tomography (PET) imaging. V H is the heavy chain variable region, V L is the light chain variable region, and C L is the light chain constant region. The variable region is shown in black, and the constant region is shown in gray were determined using BD FACSDiva software and calculated using Microsoft Excel.
| Deferoxamine-p-SCN conjugation and radiolabeling of His-Tag scFv
For DFO conjugation of His-Tag scFv, the ratio of dissolved chelating agent DFO (p-SCN-Bn-DFO) : His-Tag scFv was adjusted to a molar ratio of 3:1 and incubated for 1 hour in bicarbonate buffer (pH 9.0) at 37°C. 89 Zr was produced by a cyclotron (HM-12S;
Sumitomo Heavy Industries, Ltd), purified from excess target material 89 Y, and obtained in 1 mol/L oxalic acid. 89 Zr-oxalate solution was neutralized by the addition of 2 mol/L Na 2 CO 3 , followed by 
| Xenografts
All animal experiments were conducted in accordance with the 
| Positron emission tomography, computed tomography imaging and biodistribution of mice
Each mouse inoculated with NCI-N87 and PANC-1 cells was anesthetized by inhalation of isoflurane. 89 Zr-DFO-scFv was given into the tail vein of mice (n = 3), and a dynamic emission scan was acquired for 3 hours using a PET system (Clairvivo PET; Shimadzu). Mean amount of scFv given was 6.0 MBq/8.3 μg for H1a050 and 4.1 MBq/11.5 μg for H2a064. After the PET scan, computed tomography (CT) data were obtained using a PET/CT system (Eminence Stargate; Shimadzu).
Acquired PET data were reconstructed using 3-D-DRAMA. PET and CT images were converted to DICOM format and fused using PMOD 
| Statistical analysis
Data are presented as the mean ± SD. Statistical analysis was carried out using a nonpaired Student's t test for comparison of two groups.
Statistical significance was established at P < .05. 
| RE SULTS
| Preparation of antihuman MSLN-scFv-His-Tag in mammalian cells
In order to obtain structural authenticity and correct glycosylation pattern, scFv were generated by mammalian cells. Antihuman Although there is a difference in molecular weight of approximately one amino acid residue, a peptide of nearly the estimated molecular weight was obtained.
| Deferoxamine-p-SCN conjugation and radiolabeling of His-Tag scFv
His-Tag scFv were modified with DFO and labeled with 89 Zr. Specific activity after 89 Zr labeling was 0.496 MBq/μg and 0.365 MBq/μg for H1a050 and H2a064, respectively. In vitro stability of 89 Zr-labeled scFv after 6-hour incubation in 50% human plasma at 37°C was 
| Positron emission tomography, CT imaging and biodistribution of mice
| D ISCUSS I ON
In the present study, we prepared scFv against MSLN, a target molecule in cancers. We showed that MSLN-positive tumors in tumor-bearing mice could be visualized by PET imaging with 89 Zrlabeled anti-MSLN scFv ( Figure 6 ). The scFv domains showed high amino acid sequence identities, as well as the hypervariable region.
Complementarity determining region (CDR) was rich in L1, L2, L3, and H3 changes. Meanwhile, H2 showed only slight differences in two amino acid residues, demonstrating extremely high homology.
In addition, the "RPS" amino acid sequence of the CDRL2 domain and the "Q**DSS" amino acid sequence of the CDRL3 domain were conserved; thus, these amino acid residues strongly contributed to the antibody's affinity to human MSLN ( Figure 4B ). antigen-binding activity. The radiolabeled scFv clones were also stable in 50% plasma at 37°C for 6 hours (98.3% and 100%). In PET imaging, 89 Zr-labeled scFv clearly showed the tumor derived from NCI-N87 cancer cells strongly expressing MSLN, but did not show the tumor by PANC-1 cells weakly expressing MSLN ( Figure 6A ).
As seen from the distribution in the blood and tumors, 89 Zr-labeled scFv was quickly discharged from the blood and retained in tumors even at 3 hours post-injection. The accumulation of NCI-N87 was almost twofold that of PANC-1 ( Figure 6C ). This indicates the potential of scFv H1a050 as a rapid PET probe for MSLN-positive cancer diagnosis. The mouse antihuman MSLN 11-25 IgG antibody we developed earlier was found to be useful for in vivo near infrared fluorescence (NIRF) imaging, and 64 Cu PET imaging.
32
However, for PET imaging with 64 Cu-DOTA-11-25 IgG, it took 24-48 hours after the administration to obtain images with fine contrast. This is likely an effect of recirculation of labeled antibody by the lymphatic system by recognition of the Fc domain through the embryonic Fc receptor and weak diffusion of the antibody from the vasculature because of its size. 29 Moreover, effects such as opsonization of the Fc domain inhibit specific examination of antibody molecules as probes. Therefore, in the present study, we imaged with scFv, which is a small molecule and a fragment without the Fc domain. scFv showed fast blood clearance, but tumor clearance is also reported to be fast. [26] [27] [28] [29] In vivo visualization with scFv has been demonstrated with anti-tissue factor with a NIRF label. 35 However, with PET imaging, scFv is usually not used, and most imaging uses low molecular fragment antibody molecules such as scFv-Fc or diabody. 36, 37 The scFv prepared in the present study allowed visualization of tumors that express MSLN with PET at 3 hours after injection. As such, our antibodies would be useful for tumor imaging. There was a large amount of 89 Tc, 38 we may need to consider these methods to decrease 89 Zr accumulation in the liver.
A metallic positron emitter, 89 Zr, does not emit beta-minus particles. Therefore, radiation to the body can be controlled for greater safety. Moreover, because of its longer half-life (78.41 hours) compared to other PET nuclides, it can be used for various and more complex labeling and purification. 
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